It is hard to get excited after looking at Agilent Technologies' (NYSE:A) recent performance, when its stock has declined 15% over the past three months. However, stock prices are usually driven by a ...

As Merck received its latest FDA nod for Keytruda in ovarian cancer, Agilent gained the green light for its accompanying test to identify patients who can best benefit from the drug.  | As Merck ...

Agilent Technologies (NYSE:A) leads in scientific instrumentation, with its strong performance contributing to the S&P 500 fund ...

Agilent Technologies Inc. (NYSE: A) announced today that it will present a range of next‑generation automated workflow ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR 1 ...

Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent's inaugural Instrument Trade-In Impact Award, recognizing exceptional ...

Shares of Agilent Technologies Inc. A shed 1.61% to $127.50 Monday, on what proved to be an all-around positive trading ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...

Agilent has boosted its contract development and manufacturing organisation (CDMO) capacity with a $925 million deal to buy Biovectra, a Canadian provider of fill-and-finish services and active ...

Agilent stands out as a focused, well-managed leader in life science instruments, with strong financials and resilience amid global trade headwinds. The Ignite transformation program enhances supply ...

Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s ...

Not long after acquiring Resolution Bioscience in a deal worth more than half a billion dollars, Agilent Technologies has resolved to shutter the business, which was developing liquid biopsy tests ...